Published in Breast Cancer Res Treat on February 01, 2002
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res (2008) 1.55
Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia (2006) 1.02
Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer (2005) 1.01
Differential regulation of calcium homeostasis in adenocarcinoma cell line A549 and its Taxol-resistant subclone. Br J Pharmacol (2004) 0.93
The transglutaminase 2 gene is aberrantly hypermethylated in glioma. J Neurooncol (2010) 0.87
Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression. J Biol Chem (2012) 0.87
Luteolin induces apoptosis in multidrug resistant cancer cells without affecting the drug transporter function: involvement of cell line-specific apoptotic mechanisms. Int J Cancer (2011) 0.86
Tissue transgluaminase 2 expression in meningiomas. J Neurooncol (2008) 0.84
Label-free recognition of drug resistance via impedimetric screening of breast cancer cells. PLoS One (2013) 0.84
Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival. Mol Cancer Res (2015) 0.81
Biological functionalities of transglutaminase 2 and the possibility of its compensation by other members of the transglutaminase family. ScientificWorldJournal (2014) 0.78
Systems-scale analysis reveals pathways involved in cellular response to methamphetamine. PLoS One (2011) 0.77
Effect of CD38 on the multidrug resistance of human chronic myelogenous leukemia K562 cells to doxorubicin. Oncol Lett (2016) 0.75
Prognostic value of Transglutaminase 2 in non-small cell lung cancer patients. Oncotarget (2017) 0.75
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene (2002) 2.03
Hematopoiesis is not clonal in healthy elderly women. Blood (2008) 1.95
Socio-demographic correlates of breast-feeding in urban slums of Chandigarh. Indian J Med Sci (2006) 1.94
Expression of cone-photoreceptor-specific antigens in a cell line derived from retinal tumors in transgenic mice. Invest Ophthalmol Vis Sci (2004) 1.92
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res (2010) 1.78
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res (2006) 1.72
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res (2008) 1.55
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol (2009) 1.48
Kinase-dependent differentiation of a retinal ganglion cell precursor. Invest Ophthalmol Vis Sci (2006) 1.47
Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats. Invest Ophthalmol Vis Sci (2005) 1.40
Repression of Six3 by a corepressor regulates rhodopsin expression. Proc Natl Acad Sci U S A (2007) 1.38
Oxidative stress in glaucoma: a burden of evidence. J Glaucoma (2007) 1.36
Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One (2010) 1.36
Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. J Neurosci (2008) 1.30
Elevated hydrostatic pressure triggers mitochondrial fission and decreases cellular ATP in differentiated RGC-5 cells. Invest Ophthalmol Vis Sci (2007) 1.30
Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin Cancer Res (2008) 1.29
Transglutaminase regulation of cell function. Physiol Rev (2014) 1.28
Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther (2007) 1.27
Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther (2006) 1.24
The sigma receptor ligand (+)-pentazocine prevents apoptotic retinal ganglion cell death induced in vitro by homocysteine and glutamate. Brain Res Mol Brain Res (2004) 1.23
Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res (2007) 1.21
Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin Cancer Res (2008) 1.15
Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat (2007) 1.14
Light induces programmed cell death by activating multiple independent proteases in a cone photoreceptor cell line. Invest Ophthalmol Vis Sci (2007) 1.13
Retinal ganglion cell line apoptosis induced by hydrostatic pressure. Brain Res (2006) 1.12
Serum deprivation induces apoptotic cell death of transformed rat retinal ganglion cells via mitochondrial signaling pathways. Invest Ophthalmol Vis Sci (2005) 1.11
Testicular cancer. J Natl Compr Canc Netw (2012) 1.11
Analysis of sigma receptor (sigmaR1) expression in retinal ganglion cells cultured under hyperglycemic conditions and in diabetic mice. Brain Res Mol Brain Res (2002) 1.10
Interleukin-10 receptor signaling through STAT-3 regulates the apoptosis of retinal ganglion cells in response to stress. Invest Ophthalmol Vis Sci (2003) 1.10
Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest Ophthalmol Vis Sci (2003) 1.09
OPA1 expression in the normal rat retina and optic nerve. J Comp Neurol (2005) 1.06
Calpeptin provides functional neuroprotection to rat retinal ganglion cells following Ca2+ influx. Brain Res (2006) 1.06
Kidney cancer. J Natl Compr Canc Netw (2011) 1.06
Multidrug-resistant MCF-7 cells: an identity crisis? J Natl Cancer Inst (2002) 1.04
PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells. Autophagy (2007) 1.04
Tissue transglutaminase promotes or suppresses tumors depending on cell context. Anticancer Res (2009) 1.04
Soluble CD44 is cytotoxic to trabecular meshwork and retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci (2005) 1.02
A glaucoma-associated mutant of optineurin selectively induces death of retinal ganglion cells which is inhibited by antioxidants. Invest Ophthalmol Vis Sci (2007) 1.02
Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer (2005) 1.01
Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast Cancer Res (2013) 1.00
Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One (2011) 1.00
Kidney cancer, version 2.2014. J Natl Compr Canc Netw (2014) 0.98
Metabolic syndrome: a challenging health issue in highly urbanized Union Territory of north India. Diabetol Metab Syndr (2010) 0.97
Metastatic potential of tumor-initiating cells in solid tumors. Front Biosci (Landmark Ed) (2011) 0.97
Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 0.97
Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong. J Cancer Surviv (2013) 0.96
all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. Am J Hematol (2002) 0.96
Tissue transglutaminase (TG2) in cancer biology. Prog Exp Tumor Res (2005) 0.95
Tissue transglutaminase constitutively activates HIF-1α promoter and nuclear factor-κB via a non-canonical pathway. PLoS One (2012) 0.95
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol (2013) 0.95
Sequencing systemic therapies for metastatic kidney cancer. Curr Treat Options Oncol (2015) 0.95
Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway. J Natl Cancer Inst (2013) 0.94
Methylation of AR locus does not always reflect X chromosome inactivation state. Blood (2012) 0.93
The role of CaMKII in BDNF-mediated neuroprotection of retinal ganglion cells (RGC-5). Brain Res (2005) 0.92
Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther (2010) 0.92
Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets (2007) 0.92
Neuroprotective effects of minocycline against in vitro and in vivo retinal ganglion cell damage. Brain Res (2005) 0.92
Heat shock protein 27 delays Ca2+-induced cell death in a caspase-dependent and -independent manner in rat retinal ganglion cells. Invest Ophthalmol Vis Sci (2005) 0.91
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res (2013) 0.91
Empirically identified goals for the management of unexplained symptoms. Fam Med (2006) 0.90
Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol (2007) 0.90
Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. Int J Oncol (2002) 0.90
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer (2014) 0.90
Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res (2012) 0.90
Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship? Amino Acids (2011) 0.89
Microarray reveals complement components are regulated in the serum-deprived rat retinal ganglion cell line. Mol Vis (2007) 0.89
Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev (2013) 0.89
IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2010) 0.88
Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Curr Urol Rep (2013) 0.88
Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells. Leuk Lymphoma (2005) 0.88
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int (2014) 0.86
Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis. J Cell Physiol (2004) 0.86
Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw (2015) 0.86
Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells. Apoptosis (2007) 0.85
Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther (2011) 0.85
Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Target Oncol (2013) 0.85
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer (2013) 0.85
Retinal ganglion cell death and neuroprotection: Involvement of the CaMKIIalpha gene. Brain Res Mol Brain Res (2005) 0.85
Role of nonfeminizing estrogen analogues in neuroprotection of rat retinal ganglion cells against glutamate-induced cytotoxicity. Free Radic Biol Med (2005) 0.85
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw (2012) 0.85
Molecular-wire behavior of OLED materials: exciton dynamics in multichromophoric Alq3-oligofluorene-Pt(II)porphyrin triads. J Am Chem Soc (2006) 0.84
Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways. Int J Cancer (2014) 0.84
Label-free recognition of drug resistance via impedimetric screening of breast cancer cells. PLoS One (2013) 0.84
Novel molecular aberrations and pathologic findings in a tubulocystic variant of renal cell carcinoma. Indian J Pathol Microbiol (2014) 0.84
Antitumor metallothiosemicarbazonates: structure and antitumor activity of palladium complex of phenanthrenequinone thiosemicarbazone. Inorg Chem (2005) 0.84
Prostate cancer risk prediction based on complete prostate cancer family history. Prostate (2014) 0.84
Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer (2013) 0.83
Patient and provider attitudes toward genomic testing for prostate cancer susceptibility: a mixed method study. BMC Health Serv Res (2013) 0.83